GNRH1 and neoplasm: Specifically, it circumvents the potential adverse effects linked to GnRH agonists, such as tumor flare, and obviates the need for frequent injections, thereby eliminating injection site reactions—a common issue with injectable GnRH antagonists like Degarelix [2, 4, 5].